FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to preparing medicinal compositions for intranasal application, for example, ointment or nasal drops. Agent comprises biologically active component and the component providing stabilization of physical-chemical properties of biologically active component. As biologically active component the agent comprises immunomodulating agent taken among the group: cytokines, poludanum taken in the amount 50-400 IU per 1 ml of mixture; ridostinum taken in the amount 0.006-0.04 g per 1 ml of mixture; polyoxidonium taken in the amount 0.003-0.12 g per 1 ml of mixture; metronidazole taken in the amount 0.001-0.01 g per 1 ml of mixture; amixinum taken in the amount 0.05-0.15 g per 1 ml of mixture. Viscosity value of mixture is (1.1-30.0) x 10-3 Pa. Agent comprises additionally antiallergic medicinal agents taken among the group: ebastin, loratadine, levocabastine, azelastine, astemizol, terfenadine, chloropyramine, mebhydrolin, dimetinden taken in the amount 0.0001-0.1 g per 1 ml of mixture; vasoconstrictive preparations taken among the group: tetryzoline, oxymetazoline, phenylephrine, xylometazoline, naphazoline taken in the amount 0.0001- -0.001 g per 1 ml of mixture and regulators of cellular functions taken among the group: theophylline, sodium cromoglicate and sodium nedocrimal taken in the amount 0.0002-0.01 g per 1 ml of mixture. Except for, the agent comprises recombinant alpha-, beta- or gamma- -interferon, stabilizing agent taken among the group: polyethylene oxide, polyvinylpyrrolidone, polyvinyl alcohol, glycerol, methylcellulose, gelatin, vitamins, beta-carotene, antioxidant, Trilon B or butyloxytoluene and an anti-inflammatory agent taken among the group: diclofenac sodium, indometacin, ibuprofen, naproxen; corticosteroid preparations: hydrocortisone, fludrocortisone, flumetasone, betamethasone, mometasone, ftorcortolone, triamcinolone. Agent comprises additionally silver ions or colloidal silver, zinc sulfate and dioxydin. Invention provides the development of effective agent providing effect on place of primary introduction and multiplication of influenza virus and other respiratory viruses, good absorption capacity, optimal viscosity and distribution of agent on surface of mucosa in prolonged retaining on it. EFFECT: improved preparing method, enhanced effectiveness, valuable medicinal properties of agent. 10 cl _
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR TREATMENT OF ALLERGIC RHINITIS AND ALLERGIC CONJUNCTIVITIS | 2002 |
|
RU2220740C1 |
SUPPOSITORY | 2006 |
|
RU2322968C1 |
ANTIVIRAL AGENT | 2000 |
|
RU2187330C1 |
CURATIVE AGENT | 2000 |
|
RU2187332C1 |
ANTIVIRAL, ANTIBACTERIAL AND ANTICANDIDOSIS AGENT | 2000 |
|
RU2187328C1 |
CONDOM LUBRICANT | 2000 |
|
RU2187329C1 |
MEDICINAL PREPARATION | 2000 |
|
RU2187331C1 |
ANTIVIRAL MEDICATION - NASAL DROPS | 2010 |
|
RU2437676C1 |
MEDICATION FOR VAGINAL APPLICATION, POSSESSING CONTRACEPTIVE AND PROTECTIVE AGAINST INFECTIOUS DISEASES ACTION | 2010 |
|
RU2432961C1 |
AGENT FOR RHINITIS TREATMENT | 2002 |
|
RU2220738C1 |
Authors
Dates
2004-01-10—Published
2002-08-30—Filed